ERBB2 and breast carcinoma: In fact, several discrepancies between utilization of serum or tissue HER2 have raised to the researchers in the field such as a shortage in defining tissue positivity for HER2 due to classification system, heterogeneity of breast cancers, conversion of HER2 status and the kinetic nature of serum HER2 ECD concentrations, cut-off levels, serum interference, etc. [20].